AzTrials
AzTrials

Octogenarian Patients With Non-metastatic Resectable Colorectal CancerNCT07903129

SGA-OCRC: Prediction of 90-Day Major Adverse Postoperative Outcomes in Octogenarians With Resectable Colorectal Cancer

An observational study of Octogenarian Patients With Non-metastatic Resectable Colorectal Cancer, run by Second Affiliated Hospital, Zhejiang University, School of Medicine.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

Octogenarian patients with colorectal cancer are a growing population with substantial heterogeneity in frailty, functional reserve, nutritional status, and comorbidity. Chronological age alone does not adequately capture this variation in perioperative risk. Read more about this study

Who is it for?
Ages 80 years and older
How many people
1,000 participants
Where
No sites listed yet
Study dates
Jun 2027to Sep 2030
How long will I take part?
3 Months
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 80 years and older
  • All sexes
  • No healthy volunteers
  • Older adult

Study population: Eligible patients will be aged ≥80 years with newly diagnosed or highly suspected, non-metastatic, technically resectable colorectal cancer involving the colon or upper rectum (lower tumor margin ≥12 cm from the anal verge). Elective and expedited surgery will be eligible. Expedited surgery refers to resection after initial assessment or stabilization for tumor-related symptoms, including bowel obstruction, when immediate emergency surgery is not required. Patients requiring immediate emergency surgery for perforation, acute complete obstruction, bowel ischemia, or other life-threatening complications will be excluded. Other exclusion criteria will include previous colorectal or major abdominal surgery, metastatic disease, lower rectal cancer requiring neoadjuvant treatment, severe cognitive impairment without a reliable informant, or refusal.

Who may be able to join

  • Aged ≥80 years
  • Newly diagnosed or highly suspected, non-metastatic, technically resectable colorectal cancer involving the colon or upper rectum (lower tumor margin ≥12 cm from the anal verge)
  • Eligible for elective or expedited surgery (expedited surgery refers to resection after initial assessment or stabilization for tumor-related symptoms, including bowel obstruction, when immediate emergency surgery is not required)

Who cannot join

  • Requiring immediate emergency surgery for perforation, acute complete obstruction, bowel ischemia, or other life-threatening complications
  • Previous colorectal or major abdominal surgery
  • Metastatic disease
  • Lower rectal cancer requiring neoadjuvant treatment
  • Severe cognitive impairment without a reliable informant
  • Patient refusal
  • Withdrawal Criteria:
  • Intraoperative exploration reveals metastatic disease or tumor involvement of major organs or vessels that precludes an R0 resection

Trial locations and contacts

No sites are listed yet. Contact the study team or a site near you to ask about taking part.

Zhanhuai Wang, Dr. contact

+86 87783759

wangzhanhuai@zju.edu.cn

About this study

Official title: Simplified Geriatric Assessment-Based Prediction of 90-Day Major Adverse Postoperative Outcomes in Octogenarian Patients With Non-metastatic Resectable Colorectal Cancer: Protocol for a Prospective Multicenter Cohort Study (SGA-OCRC)

Octogenarian patients with colorectal cancer are a growing population with substantial heterogeneity in frailty, functional reserve, nutritional status, and comorbidity. Chronological age alone does not adequately capture this variation in perioperative risk. Although geriatric assessment has been increasingly incorporated into the care of older patients with cancer, comprehensive geriatric assessment can be difficult to implement routinely in colorectal surgical practice.

The SGA-OCRC study is a prospective, multicenter observational cohort study designed to address this gap. The investigators will evaluate whether a pragmatic simplified geriatric assessment provides prognostic information beyond conventional clinical, laboratory, and tumor-related risk factors in patients aged ≥80 years with non-metastatic, resectable colorectal cancer. The study will develop and internally validate a preoperative prediction model for 90-day major adverse postoperative outcomes using contemporary prediction-model methodology. Particular attention will be given to model calibration, clinical utility, and internal validation rather than predictor selection based solely on statistical significance.

Keywords
Octogenarians, colorectal cancer, geriatric assessment, postoperative complications, risk prediction model
Medical subject headings
Colorectal Neoplasms, Postoperative Complications

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT07903129
Study groupRoleWhat they receive
Surgical CohortPatients who undergo curative-intent colorectal resection will form the primary analysis cohort
Non-surgical CohortPatients who fail to receive surgical resection will form the primary analysis cohort

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. 90-day major adverse postoperative outcomes (MAPO)

    The primary outcome is 90-day major adverse postoperative outcomes (MAPO), defined as the occurrence of any of the following:

    1. Clavien-Dindo grade ≥III complication: a postoperative complication requiring surgical, endoscopic, or radiological intervention, or more intensive treatment for life-threatening complications.
    2. Unplanned ICU admission: an unexpected transfer to the intensive care unit for postoperative monitoring or organ support.
    3. Mechanical ventilation >48 h: the need for invasive mechanical ventilation for more than 48 hours after surgery.
    4. 30- or 90-day all-cause mortality: death from any cause within 30 or 90 days after surgery.
    5. Unplanned readmission within 90 days: an unexpected hospital admission within 90 days after discharge from the index hospitalization.

    The primary composite outcome will be analyzed as a binary variable. Patients will be classified as having MAPO if at least one qualifying event occurs within 90 days after surgery.

    Measured: 90 days after surgery

Secondary outcomes (4)
  1. Major pulmonary complications

    Major postoperative pulmonary complications (PPCs) will be defined as clinically significant pulmonary complications occurring within 90 days after surgery that require active treatment or substantial respiratory support. Definitions will be based on the European Perioperative Clinical Outcome (EPCO) recommendations and the Standardized Endpoints in Perioperative Medicine-Consensus for Perioperative Clinical Outcomes (StEP-COMPAC) recommendations.

    Major PPCs will be analyzed as a binary outcome and reported as the number and proportion of patients who experience at least one qualifying event within 90 days after surgery. Each component will also be reported separately as the number and proportion of affected patients. Patients experiencing multiple pulmonary complications will be counted only once in the composite outcome.

    Measured: 90 days after surgery

  2. KDIGO-defined acute kidney injury

    AKI severity will be classified as KDIGO Stage 1-3 according to the highest stage reached based on either serum creatinine or urine output criteria. Any AKI will be defined as KDIGO Stage 1-3, whereas moderate-to-severe AKI will be defined as KDIGO Stage 2-3. Stage 3 AKI will be recorded separately because of its clinical severity and potential need for renal replacement therapy.

    AKI will be analyzed as a binary outcome, with any AKI (KDIGO Stage 1-3) reported as the number and proportion of affected patients, with a 95% CI. The numbers and proportions of patients in each KDIGO stage will also be reported. Moderate-to-severe AKI (Stages 2-3) and Stage 3 AKI will be summarized separately.

    Measured: 90 days after surgery

  3. Postoperative delirium

    Postoperative delirium (POD) will be assessed using the 4 'A's Test (4AT). The 4AT is a brief, validated tool for detecting delirium in older hospitalized patients and has also been evaluated in postoperative settings. A score of ≥4 will be considered a positive delirium screen.

    Patients will be assessed daily from postoperative day 1 through postoperative day seven or hospital discharge, whichever occurs first. Delirium will be defined as an acute and fluctuating disturbance in attention and awareness accompanied by an additional disturbance in cognition, consistent with established diagnostic criteria. Whenever feasible, patients with a positive 4AT screen (≥4) will undergo clinical confirmation by a trained investigator using DSM-5-based criteria.

    The incidence of POD will be analyzed as a binary outcome and reported as the number and proportion of affected patients, with a 95% CI. Delirium duration will be summarized using the median and interquartile range (IQR), as appropriate.

    Measured: 90 days after surgery

  4. Anastomotic leakage

    Anastomotic leakage (AL) will be defined according to the International Study Group of Rectal Cancer (ISREC) criteria as a defect in the intestinal wall at the anastomotic site, including the suture or staple line, resulting in communication between the intraluminal and extraluminal compartments. The diagnosis may be established by clinical, radiological, endoscopic, or operative findings.

    Anastomotic leakage will be classified according to the ISREC grading system. Grade A leakage requires no change in clinical management; Grade B leakage requires active therapeutic intervention but can be managed without relaparotomy; and Grade C leakage requires relaparotomy.

    The incidence of any AL (Grades A-C) will be analyzed as a binary outcome and reported as the number and proportion of affected patients, with a 95% CI. The numbers and proportions of patients with Grade A, B, and C leakage will be reported separately. Grade B and Grade C leakage will also be summarized separately to describe

    Measured: 90 days after surgery

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted29 Oct 2026
  2. Study startJun 2027 (estimated)
  3. Primary completionJun 2030 (estimated)
  4. Study completionSep 2030 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
1,000 participants (estimated)
Target duration
3 Months
IDs, dates and publications
ClinicalTrials.gov ID
NCT07903129
Sponsor's protocol ID
2026-1065
Status last verified
Sep 2026
First submitted
7 Oct 2026
Last updated
29 Oct 2026
Results posted
No
Data monitoring committee
Yes
Individual data sharing
Yes

Questions about this trial

What is this clinical trial studying?

An observational study of Octogenarian Patients With Non-metastatic Resectable Colorectal Cancer, run by Second Affiliated Hospital, Zhejiang University, School of Medicine.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 29 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Zhanhuai Wang, Dr. (+86 87783759, wangzhanhuai@zju.edu.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

90-day major adverse postoperative outcomes (MAPO) (time frame: 90 days after surgery). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Oct 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in